Evidence map›Paper›PMID 33121007›Full record

ArticleCancers2020

Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study.

Ulrich-Frank Pape, Stefan Kasper, Johannes Meiler, Marianne Sinn, Arndt Vogel, Lothar Müller, Oswald Burkhard, Karel Caca, Steffen Heeg, Petra Büchner-Steudel and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 3 countries.

Ulrich-Frank PapeDepartment of Hepatology and Gastroenterology, Campus Charité Mitte and Virchow Klinikum, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.
Stefan KasperDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, 45147 Essen, Germany.
Johannes MeilerDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, 45147 Essen, Germany.ORCID 0000-0001-7284-2352
Marianne SinnDepartment of Medical Oncology, Universitäts Klinikum Hamburg-Eppendorf, 20251 Hamburg, Germany.
Arndt VogelDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0003-0560-5538
Lothar MüllerOnkologische Schwerpunktpraxis Leer-Emden-Papenburg, 26789 Leer, Germany.
Oswald BurkhardOnkologische Praxis, 67547 Worms, Germany.
Karel CacaKlinikum Ludwigsburg, 71640 Ludwigsburg, Germany.
Steffen HeegDepartment of Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 70085 Freiburg, Germany.ORCID 0000-0003-3368-0703
Petra Büchner-SteudelMartin-Luther-University Halle Wittenberg, Medizinische Fakultät, Universitätsklinik und Poliklinik für Innere Medizin I, 06120 Halle (Saale), Germany.
Victor Rodriguez-LavalHospital Universitario de La Princesa, 28006 Madrid, Spain.ORCID 0000-0002-4581-0993
Anja A KühliPATH.Berlin, Core Unit of the Charité, Hindenburgdamm, 12203 Berlin, Germany.
Ruza ArsenicInstituts für Histologische und Zytologische Diagnostik AG, 5000 Aarau, Switzerland.
Holger JansenInstitute for Medical Immunology, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.
Peter TreasurePeter Treasure Statistical Services Ltd., Stow Bridge PE34 3NR, UK.
Nalân UtkuInstituts für Histologische und Zytologische Diagnostik AG, 5000 Aarau, Switzerland.
Charité - Universitätsmedizin Berlin · DEEssen University Hospital · DEPraxis für Hämatologie und Onkologie · DEAsklepios Klinik St. Georg · DECellAct Pharma (Germany) · DEHospital Universitario de La Princesa · ESKlinikum Ludwigsburg · DEMartin Luther University Halle-Wittenberg · DEMedizinische Hochschule Hannover · DERoyal Statistical Society · GBUniversität Hamburg · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. In a Phase II trial, 27 patients with advanced biliary tract cancers (BTC) were randomised 1:1 to CAP7.1 plus best supportive care (BSC), or BSC alone, with crossover to CAP7.1 upon disease progression. The primary objective was disease control rate (DCR) following 28-day cycles of CAP7.1 (200/150 mg/m

Indexed as

biliary tract cancerCAP7.1cholangiocarcinomaunresectable

Identifiers

PMID33121007
PMCPMC7692271
OpenAlexW3097113656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.